Bayer's ON-TRK study record updated, remains active not recruiting at 54 patients

Bayer's record update this week covered a single long-running observational study of its drug VITRAKVI.

• The "PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib," known as ON-TRK (NCT04142437), is sponsored by Bayer and remains listed as active, not recruiting. The study is observing the effectiveness and tolerability of VITRAKVI (larotrectinib) during routine use in patients with locally advanced or metastatic TRK fusion cancer.¹ The study has enrolled 54 participants across tumor types including gastrointestinal cancer, head and neck cancer, soft tissue sarcoma, primary central nervous system cancer, lung cancer, melanoma, and a pediatric cohort.¹ Participants are being observed over a period of 24 to 60 months.¹ Primary completion is estimated for 2029-12-31, with study completion estimated for 2030-08-01.